3 March 2021 - On Target Laboratories today announced that the U.S. FDA has accepted its new drug application for priority ...
25 February 2021 - RT001 also granted fast track designation by FDA in Friedreich’s ataxia. ...
23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...
23 February 2021 - If approved, the vaccine may help reduce the risk of tick-borne encephalitis for people traveling to endemic ...
16 February 2021 - FDA target action date is 16 August 2021 ...
16 February 2021 - FBX-101 is a first-in-human gene therapy utilising an adeno-associated virus to deliver a functioning copy of the ...
16 February 2021 - FDA stated it is not currently planning to hold an advisory committee meeting. ...
10 February 2021 - Polaryx Therapeutics announced today that it has received both rare paediatric disease and orphan drug designations for ...
12 February 2021 - Rescindo Therapeutics announced today that the U.S. FDA has granted orphan drug designation and rare paediatric disease ...
5 February 2021 - Actinogen is pleased to announce that the United States FDA has granted Actinogen’s drug Xanamem rare paediatric ...
3 February 2021 - Aruvant Sciences today announced that the EMA granted PRIME designation to ARU-1801, a one-time investigational gene therapy ...
2 February 2021 - CHK-336 on track for Phase 1 clinical trial initiation in the second half of 2021. ...
1 February 2021 - Janssen announced today that the CHMP of the EMA will perform an accelerated assessment of the ...
1 February 2021 - U.S. Food and Drug Administration assigned an action date of 30 May 2021. ...
28 January 2021 - U.S. FDA also grants two orphan drug designations for the company’s gene therapy programs for Gaucher disease ...